Initial scepticism about the significance of antiganglioside antibodies is being replaced by a widespread realisation that these antibodies directly contribute to the pathogenesis of neuropathy. Two incompletely resolved issues which cast doubt on this relation are that raised concen Glycolipid terminology, structure, and function An early hurdle to cross concerns the complexities of glycolipid and ganglioside terminology. Glycosphingolipids are composed of the long chain aliphatic amine sphingosine (acylated ceramide) attached to one or more sugars (hexoses). The ceramide is immersed in the membrane lipid bilayer with the carbohydrate structure exposed extracellularly. A single hexose linked to ceramide (monohexosyl-ceramide) is termed a cerebroside, the most abundant of which in humans is galactocerebroside (galactosyl-ceramide). Sulphatide is galactocerebroside sulphated in the carbon-3 position and is a major component of peripheral nerve myelin and an autoantigen in predominantly sensory neuropathies. [5] [6] [7] [8] [9] Gangliosides are complex glycosphingolipids that, by definition, must contain at least one sialic acid residue. Sialic acid is a generic term for N-acylneuraminic acid, the acyl group generally being acetyl in the human nervous system (as opposed to glycolyl), hence N-acetylneuraminic acid, commonly abbreviated to NeuNAc or NANA. The sialic acid(s) are attached to the internal or the terminal galactose of an oligosaccharide core composed of up to four sugars with the following sequence: ceramide-glucose-galactose-N-acetylgalactosamine-galactose. Traditionally, gangliosides are named according to Svennerholm'0 II with the following formula: G refers to ganglio; M, D, T, and Q refer to the number of sialic acid residues (mono, di, tri, and quad respectively); arabic numerals and lower case letters refer to the sequence of migration as determined by thin layer chromatography. Although dependent on the solvent system used, bulky gangliosides with a longer oligosaccharide core and more sialic acid will migrate more slowly than the smaller gangliosides. For example, for three of the monosialogangliosides, GM1 (having a four sugar oligosaccharide core, Cer-Glc-Gal-GalNAc-Gal) migrates more slowly than GM2 (a three sugar oligosaccharide, Cer-Glc-Gal-GalNAc), which migrates more slowly than GM3 (a two sugar oligosaccharide, Cer-Glc-Gal). Likewise, GDlb runs ahead of GTlb, which runs ahead of GQlb, as they contain two, three, and four sialic acids respectively. The figure shows the structure of GDlb. There are four major gangliosides in the brain (GM1, GDla, GDlb, GTlb) and many minor gangliosides in brain and peripheral nerve tissues, which are developmentally regulated and spatially segregated in a wide range of patterns across different species. Many different gangliosides can be autoantigens in peripheral neuropathy, some of which have not been identified.'
Paragloboside is a neutral glycolipid (Cer-Glu-GalGlcNAc-Gal), which, when sialylated on the terminal galactose (sialosylparagloboside, SGP), is a major peripheral nerve glycolipid, also known as LMl.*2 Substitution of the terminal sialic acid for sulphated glucuronic acid forms sulphated glucuronyl paragloboside (SGPG). '3 14 Both LMI and SGPG are also important peripheral nerve autoantigens in neuropathy.8 13 All antiglycolipid antibodies associated with neuropathy react with epitopes on the carbohydrate region of the glycolipid molecules. Because these carbohydrate structures are often present on several different glycolipids, glycoproteins, and other carbohydrate rich molecules such as bacterial lipopolysaccharides, there is considerable potential for shared reactivity. For example, (a) autoantibodies that react with the sulphated glucuronic acid epitope on SGPG also react with similar epitopes on many other neural glycoproteins including the myelin associated glycoprotein (MAG) 13 Gal(,B1-3)GalNAc epitope found on GM1 ganglioside is also present on asialo-GM1 and GDlb (see figure) [17] [18] [19] [20] and the complete GM1 carbohydrate sequence is present on Campylobacter jejuni lipopolysaccharide (LPS),2' Campylobacter enteritis being a common prodromal infection in patients with Guillain-Barre syndrome,22-25 a proportion of whom have anti-GM1 antibodies.26 27 Glycolipids, including gangliosides, regulate many diverse physiological processes,28 29 Antiganglioside antibody assays: methodology and interpretation Assaying serum samples for antiganglioside and antiglycolipid antibodies is a process with many pitfalls. There is no standardised assay method and the literature on this subject is crowded with different protocols31 that claim superiority. Two multicentre studies with coded samples have shown good agreement on clearly positive or negative cases but discrepancies appear with borderline samples, which may nevertheless be of important clinical relevance.3233 Most centres use a combination of enzyme linked immunosorbent assay (ELISA) with thin layer chromatography overlay as a confirmatory test. Critical factors that influence assay results include (a) the choice of ELISA plates, taking into account manufacture related batch to batch variations and subsequent storage conditions; (b) the temperature at which the assay is performed; (c) the duration of serum incubation; (d) washing and blocking buffer composition, particularly the presence or absence of detergent and the choice of blocking protein; (e) sample layout on ELISA plates, with particular attention to plate stacking artefacts and edge effects. These factors need to be built into stringent quality control practice in all laboratories performing assays, particularly when results influence decisions about diagnosis and clinical management.
Assay results are usually reported as titres calculated by end point analysis (the lowest serum dilution that still gives a raised optical density reading by ELISA). When interpreting an assay result, consideration must be given to the methodology used and the normal range established for that laboratory. Because antiganglioside antibodies form part of the normal antibody/autoantibody repertoire,3435 they are commonplace in normal and disease control serum samples. The first clinical syndrome in which antiglycolipid antibodies were identified was the IgM paraproteinaemic neuropathy associated with anti-MAG antibodies.4142 As well as reacting with MAG and other glycoproteins present in peripheral nerve, it was established that the anti-MAG paraproteins also reacted with the previously unknown acidic glycolipid, SGPG, and its related homologue, sulphated glucuronyl lactosaminyl paragloboside (SGLPG).13-15 The clinical syndrome is of a relatively benign, late onset, chronic sensorimotor demyelinating neuropathy, often associated with tremor.4344 A pathological feature of note in nerve biopsies is the presence of widely spaced myelin.4446 The anti-MAG specificity accounts for 50% of patients with IgM paraproteinaemic neuropathy; most of the remainder react with other glycolipids or gangliosides.1 Some anti-MAG paraproteins cross react with sulphatide67 and in addition, sulphatide can be a specific and sole antigen in patients with IgM paraproteinaemic, predominantly sensory, neuropathy.5-7 It is important to recognise, when evaluating cases of late onset demyelinating neuropathy, that low level paraproteins may be easily missed by standard electropheretic techniques and that sensitive screening methods should be employed.
Another increasingly well defined paraproteinaemic neuropathy syndrome is a chronic large fibre sensory neuropathy with prominent ataxia, first described in a single case report almost a decade ago47 and subsequently reported by several groups.48-5' In these cases the IgM paraprotein reacts with gangliosides bearing NeuNAc(a2-8)NeuNAc linked disialosyl groups, including GD3, GDlb, GTlb, and GQlb (figure). There is some variation in the fine specificity of the antibody between cases although the clinical pattern is fairly uniform. Some of these patients also have cold agglutinin disease by virtue of the presence of sialylated glycoprotein epitopes on human red blood cells. In addition, some cases have been reported with intermittent opthalmoplegia,47 thus producing a clinical syndrome reminiscent of Miller Fisher syndrome in which antibodies to disialylated gangliosides are also found.5456
Interest in multifocal motor neuropathy with demyelinating conduction block57 has been intense since it was recognised that patients with this syndrome may have antibodies to GM1 gangloiside.58 Early reports indicating a significant association between anti-GM1 antibodies and motor neuron disease/amyotrophic lateral sclerosis59 60 were not confirmed by others3738406'-63 although there do seem to be very rare, unusual cases in which this occurs. [17] [18] [19] We screen all patients with predominantly lower motor neuron syndromes for anti-GMI antibodies. Many patients with multifocal motor neuropathy and anti-GM1 antibodies have a fairly stereotyped clinical picture comprising a chronic asymmetric motor syndrome, usually with distal onset in an upper limb, as previously described.20 [64] [65] [66] We have not found further subdivisions on the basis of antiganglioside serology useful, although they have been reported.67 These patients respond well, albeit temporarily, to intravenous immunoglobulin68 which is our routine treatment and can be regularly repeated. Our own experience with cyclophosphamide has been disappointing (lack of sufficient efficacy to warrant the high risks of toxicity) although others report success. 69 Antiganglioside antibodies are also found in acute peripheral neuropathies where they appear transiently and are predominantly of the IgG class. The most clearly defined association is between anti-GQlb ganglioside antibodies and Miller Fisher syndrome.54-56 The antiGQlb antibodies cross react with GTla in the series of cases reported by Chiba et a170 and in all our cases to date (14/14) and with GDlb, GD3, or both in about half of our cases. Anti-GQlb reactivity seems to specifically mark the presence of ophthalmoplegia: we have recently identified a case of acute ataxic, areflexic neuropathy without opthalmoplegia whose serum samples reacted only with GDlb and GD3, thereby lending support to this view. A recent report indicates that anti-GQlb antibodies are also present in Bickerstaffs brain stem encephalitis, suggesting that there may be a common aetiological thread to both these conditions.71
In Guillain-Barre syndrome, a wide variety of antiganglioside antibodies have been reported in up to 50% of cases in different series (table); although no unifying patterns have yet emerged, they may do so in the future. Considerable debate surrounds the significance of anti-GM1 antibodies in Guillain-Barre syndrome. In some studies, anti-GM1 antibodies mark a particularly severe form of the illness with prominent motor axonal involvement and poor recovery,262772 although this association is refuted by others.7374 This issue may be resolvable by further subclassification of anti-GM1 antibodies by fine specificity. In this regard, our recent studies on a panel of cloned human anti-GM1 antibodies75 have shown considerable heterogeneity in their ability to bind antigen under different conditions and in their patterns of tissue reactivity. This may account for the apparent diversity of clinical expression of anti-GM1 antibody associated neuropathies and neuronopathies.
The pathogenic relevance of antiglycolipid antibodies Despite considerable anomalies and complexities, good evidence is beginning to emerge from a variety of experimental models to support a direct role for antiganglioside antibodies in causing neuropathy. Clearly, other factors including cellular immune mechanisms may play a central part in pathogenesis. The subject is complicated by many factors common to developing an animal model for disease including qualitative and quantitative variations in glycolipid antigen composition in nerves from different species and the lack of well defined human antibodies for pathogenesis studies. The generation of disease associated human monoclonal antibodies should help to resolve this issue. 75 Antibodies to SGPG, as found in the "anti-MAG" IgM paraproteinaemic neuropathy have been shown to cause demyelination and other pathological changes including widening of myelin lamellae, when injected locally into rodent nerve7677 and after systemic passive transfer to the chicken. 78 An intriguing case of anti-MAG IgM paraproteinaemic neuropathy occurring in conjunction with hereditary motor and sensory neuropathy has been described,79 raising the possibility that pre-existing peripheral nerve abnormalities may predispose to the development of antinerve antibodies, a fact long recognised in experimental models of nerve injury.80
Experimental studies on anti-GM1 antibodies have shown a variety of neuropathic effects including demyelination and conduction block81-84 although these studies 
